Measured Wealth Private Client Group’s Indivior Pharmaceuticals INDV Stock Holding History

Measured Wealth Private Client Group’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550K	Buy	+13,398	New	+$486K	0.13%	111

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Measured Wealth Private Client Group's INDV Position: Q2 2026 in Review

Measured Wealth Private Client Group opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 13,398 shares worth $550K. The stake represents 0.13% of the portfolio and ranks #111 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Measured Wealth Private Client Group held 13,398 shares of Indivior Pharmaceuticals worth $550K as of Q2 2026.
Indivior Pharmaceuticals was a new Measured Wealth Private Client Group position in Q2 2026.
Indivior Pharmaceuticals made up 0.13% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #111 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.